Pipeline Keenova eyes Xiaflex as first drug for plantar fibromatosis PharmaphorumKeenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet.Rare DiseaseRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Keenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AstraZeneca, Ionis drug fails big heart disease study in major setbackNext: Roche scraps two Ionis-partnered Huntington’s drugs Related Stories Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026 Pipeline Roche scraps two Ionis-partnered Huntington’s drugs pharminent July 9, 2026
